Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) Shares Outstanding (2022 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Shares Outstanding for 4 consecutive years, with $5.4 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 230.17% to $5.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.4 million through Dec 2025, up 230.17% year-over-year, with the annual reading at $2.0 million for FY2025, N/A changed from the prior year.
  • Shares Outstanding for Q4 2025 was $5.4 million at Neuphoria Therapeutics, up from $2.4 million in the prior quarter.
  • The five-year high for Shares Outstanding was $969.4 million in Q2 2022, with the low at $454465.1 in Q2 2023.
  • Average Shares Outstanding over 4 years is $123.1 million, with a median of $1.9 million recorded in 2025.
  • The sharpest move saw Shares Outstanding plummeted 99.95% in 2023, then skyrocketed 230.17% in 2025.
  • Over 4 years, Shares Outstanding stood at $969.4 million in 2022, then tumbled by 99.95% to $454465.1 in 2023, then soared by 258.37% to $1.6 million in 2024, then surged by 230.17% to $5.4 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $5.4 million, $2.4 million, and $2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.